{'_ty': ['FLA'], '_au': ['Moland, E.S.', 'Kim, S.Y.', 'Hong, S.G.', 'Thomson, K.S.'], 'parent': {'_t2': ['CXT0239A 01964399 unassign'], 'parent': {'_jn': ['Clinical Microbiology Newsletter'], '_t1': ['CXT0239A 01964399'], '_cr': ['Copyright (c) 2008 Elsevier Inc.'], 'parent': {'_t0': ['CXT0239A'], '_pd': ['20080505'], '_vn': ['4.0'], 'parent': {}}}}, '_la': ['EN'], '_t3': ['CXT0239A 01964399 unassign 08000226'], '_ti': ['Newer @b-Lactamases: Clinical and Laboratory Implications, Part I'], '_ab': ['For optimal patient care, clinical laboratories should be capable of detecting clinically significant, novel @b-lactamases produced by gram-negative pathogens. However, with over 700 @b-lactamases now described, it is a struggle to keep abreast of the various types of @b-lactamases, their clinical relevance, and methods for detection. Furthermore, the increasing prevalence of isolates that produce multiple @b-lactamases increases the difficulty of accurate detection. Clinical Laboratory Standards Institute (CLSI, formerly NCCLS) recommendations for detection of @b-lactamases do not keep pace with this rapidly evolving field. While perfection may not always be possible, it is important that clinical laboratories provide a relevant diagnostic service to ensure appropriate antibiotic therapy and infection control. Part I of this article will provide a brief discussion of extended-spectrum @b-lactamases and methods for their laboratory detection.'], '_ii': ['S0196-4399(08)00022-6', '[DOI] 10.1016/j.clinmicnews.2008.04.004'], '_ca': ['Ellen Smith Moland. Center for Research in Antiinfectives and Biotechnology, Department of Medical Microbiology and Immunology, Creighton University School of Medicine, Omaha, Nebraska'], '_li': ['EN'], '_mf': ['[XML Cit] 08000226']}